Navigation Links
IntelliCell BioSciences Signs Technology Licensing Agreement with Stem Cells 21 Thailand
Date:4/10/2012

NEW YORK, April 10, 2012 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("Company") (OTCQB: SVFC.PK) announced today that the Company has signed a technology licensing agreement with Stem Cells 21 of Thailand, http://www.StemCells21.com. Stem Cells 21 is led by Dr. Chatchai Sribundit MD, a fellow of the College of Anti-ageing Medicine and a member of the National Olympic Committee and Mr. Paul Collier, the Managing Director for the Stem Cells 21.  They have been in the cellular treatment business for over 11 years in Thailand and have a vast amount of experience.  They run the Absolute Health Integrative Medical Center in Bangkok. In partnership with clinics and hospitals, they manage patient care for foreigners traveling to Thailand for medical care. Their partner laboratories and physicians have developed a range of treatment protocols using either umbilical cord blood-derived adult stem cells or adipose-derived cells, from the patient's own body for a wide variety of progressive and debilitating diseases.

Dr. Steven Victor, Chairman of IntelliCell BioSciences stated, "We are excited to sign this technology licensing agreement in Thailand with Stem Cells 21.  With Dr. Chatchai Sribundit and Mr. Paul Collier's extensive experience in cellular therapy, our technology can be utilized to its fullest potential.  We look forward to working with Stem Cells 21 and the Absolute Health Integrative Medical Center in Bangkok to advance the science of adult autologous vascular cellular therapy in Thailand."

About IntelliCell BioSciences
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous vascular cells (HCT/P's) derived from the blood vessels in the adult adipose tissue. IntelliCell BioSciences has developed its own patent pending protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell will also be seeking to enter into technology licensing agreements that cover a particular international territory or country.

Forward-Looking Statements
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

Contact:
IntelliCell BioSciences, Inc.
Rubenstein Investor Relations
Contact: Tim Clemensen
Email Contact: TClemensen@rubensteinir.com
(212) 843-9337  


'/>"/>
SOURCE IntelliCell BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Regado Biosciences, Inc. to Present at Needham & Companys 11th Annual Healthcare Conference in New York, NY
2. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
3. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
4. Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA
5. Amarantus BioSciences to Present at the 2012 National Investment Banking Association Conference in New Orleans
6. Amarillo Biosciences Appoints Dr. Stephen Chen as Chairman and CEO
7. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
8. GeneLink Biosciences Completes Sale of GeneWize Life Sciences
9. Ambit Biosciences to Present at Two Upcoming Investor Conferences
10. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
11. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Regular discussions on a range of subjects ... the two entities said Poloz. Speaking at a ... , he pointed to the country,s inflation target, which ... "In certain areas ... have common economic goals, why not sit down and address ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... Md. , June 23, 2016 A person ... from the crime scene to track the criminal down. ... the U.S. Food and Drug Administration (FDA) uses DNA evidence ... Sound far-fetched? It,s not. The FDA ... sequencing to support investigations of foodborne illnesses. Put as simply ...
(Date:6/23/2016)... NEW YORK , June, 23, 2016  The ... students to envision new ways to harness living systems ... of Modern Art (MoMA) in New York ... more than 130 participating students, showcased projects at MoMA,s ... included Paola Antonelli , MoMA,s senior curator of ...
Breaking Biology Technology:
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
Breaking Biology News(10 mins):